In summary, these results support a relevant role of the GAS6/AXL system in the immune response against COVID-19, suggesting them as early markers of disease prognosis and GAS6/AXL targeting as plausible clinical therapy for COVID-19 patients. The gene discussed is GAS6; the disease is COVID-19.